.png){kind=icon}
.png){kind=icon}
Return
Chronological survival improvement over time with oxaliplatin-based chemotherapy plus targeted agents in metastatic colorectal cancer: an ARCAD database study
.png){kind=icon}
OA
AI
DOI：10.1016/j.ejca.2025.116034.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• Oxaliplatin-based chemotherapy with molecular targeted agents improved CRC survival • OS, PFS, and PPS progressively improved from 2004 to 2017 • Improvements were most pronounced for left-sided and RAS wild-type tumors • Subsequent-line and biomarker-driven treatments have improved survival outcomes • Novel strategies are needed for right-sided and RAS-mutated metastatic CRC
Keywords:
oxaliplatin-based doublet chemotherapy
bevacizumab
anti-epidermal growth factor receptor antibody
metastatic colorectal cancer
Aide et Recherche en Cancérologie Digestive
clinical outcome
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
7.1
Papers:
2.6W
Citations:
3.8W
Organization
View more organizations